Arcturus Therapeutics Holdings Inc. (ARCT)
Drugs • Health Care
July 28, 2026 Arcturus Therapeutics Set to Announce Second Quarter Financial Results Arcturus Therapeutics is set to release its second-quarter financial results on August 6, 2026, followed by a conference call for stakeholders. The company highlights its innovative mRNA therapies and strategic collaborations, aiming to provide insights into its operational performance and future direction.
July 20, 2026 Arcturus Therapeutics to Showcase Innovations at Canaccord Genuity Conference Arcturus Therapeutics will showcase its mRNA advancements at the Canaccord Genuity Conference on August 11, 2026. The company will discuss its innovative therapies targeting rare diseases and its strategic collaborations in the biotechnology field.
July 02, 2026 Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific Arcturus Therapeutics has announced a strategic collaboration with Thermo Fisher Scientific to advance its mRNA therapy ARCT-032 for cystic fibrosis. This partnership aims to support the critical Phase 3 development and potential commercialization of the therapy, utilizing Thermo Fisher's comprehensive drug development solutions.
May 26, 2026 Arcturus Therapeutics Set to Present at 2026 Jefferies Global Healthcare Conference Arcturus Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 4, showcasing its advancements in mRNA therapeutics. The event will provide insights into the company's innovative approaches to treating rare diseases and ongoing projects.
May 07, 2026 Arcturus Therapeutics Reports Q1 2026 Financial Results and Significant Pipeline Developments Arcturus Therapeutics has announced its Q1 2026 financial results, showcasing significant progress in its rare disease pipeline and new executive appointments. The company has initiated a Phase 2 study for an inhaled mRNA therapy for cystic fibrosis and is preparing for pivotal trials in its OTC deficiency program, despite reporting a net loss for the quarter.
April 27, 2026 Arcturus Therapeutics Set to Release Q1 2026 Financial Results and Corporate Update Arcturus Therapeutics will report its Q1 2026 financial results on May 7. The company, known for its innovative RNA medicines, has a robust pipeline targeting rare diseases and will discuss its performance during a conference call.
March 05, 2026 Arcturus Therapeutics Announces Participation in Investor Conference Arcturus Therapeutics will participate in the Leerink Partners 2026 Global Healthcare Conference, showcasing its commitment to mRNA therapies and investor engagement. The event will feature insights into its strategic direction and ongoing projects, including collaborations and a promising therapeutic pipeline.
March 03, 2026 Arcturus Therapeutics Reports Q4 and FY 2025 Financial Results and Pipeline Updates Arcturus Therapeutics reported a significant decline in revenue for Q4 and FY 2025, with a net loss of $29.1 million in Q4. Despite financial challenges, the company is advancing key clinical programs, including a Phase 2 study for cystic fibrosis and developments targeting OTC deficiency. The firm also achieved milestones in mRNA vaccine development.
March 03, 2026 Arcturus Therapeutics Holdings Inc. Announces 2025 Annual Report: A Year of Challenges and Strategic Developments Arcturus Therapeutics' 2025 annual report reveals a significant revenue decline and operational losses, yet showcases advancements in its clinical pipeline and strategic collaborations for future growth. The company navigates financial difficulties while pursuing innovative mRNA therapies.
February 17, 2026 Arcturus Therapeutics to Unveil Fourth Quarter and Fiscal Year 2025 Financial Results Arcturus Therapeutics is set to release its Q4 and fiscal year 2025 financial results on March 3, 2026. The company will host a conference call to discuss results and future strategies in mRNA therapeutics.
January 08, 2026 Arcturus Therapeutics to Showcase Innovations at J.P. Morgan Healthcare Conference Arcturus Therapeutics will present its latest mRNA innovations at the 2026 J.P. Morgan Healthcare Conference, highlighting its strategic direction and advancements in rare disease therapies. The company aims to address critical health challenges with its proprietary mRNA technologies and robust pipeline.
November 24, 2025 Arcturus Therapeutics to Showcase Innovations at Upcoming Investor Conference Arcturus Therapeutics will present its innovative mRNA advancements at the Piper Sandler Healthcare Conference on December 2, 2025. The company highlights its proprietary technologies and strategic collaborations, positioning itself as a leader in mRNA medicine and vaccines.
November 12, 2025 Arcturus Therapeutics Reports Q3 2025: Transition to Commercialization Faces Challenges Arcturus Therapeutics reported a net loss of $13.44 million in Q3 2025, attributed to decreased revenue and high operational costs. Despite challenges, the approval of their KOSTAIVE® vaccine in Japan and progress in other therapeutic programs highlight their innovative potential in the biotech sector.
November 10, 2025 Arcturus Therapeutics Reports Q3 2025 Financial Results and Pipeline Advancements Arcturus Therapeutics reported a Q3 2025 revenue of $17.2 million, a significant decrease from 2024. The company is advancing its mRNA therapies for cystic fibrosis and OTC deficiency, despite challenges in the market and a widening net loss. Upcoming trials and collaborations aim to enhance their position in the biotechnology sector.
November 04, 2025 Arcturus Therapeutics Announces Participation in Key Investor Conferences Arcturus Therapeutics is participating in two major investor conferences to enhance its visibility and attract investors. With innovations in mRNA technology, the company aims to address rare and infectious diseases, showcasing its commitment to advancing healthcare solutions.
October 28, 2025 Arcturus Therapeutics Set to Release Q3 Financial Results on November 10, 2025 Arcturus Therapeutics is set to announce its Q3 financial results on November 10, 2025, with a conference call scheduled for the same day. The company, known for its mRNA innovations, continues to advance its therapeutic pipeline and collaborative ventures.
October 22, 2025 Arcturus Therapeutics Announces Encouraging Interim Phase 2 Data for Cystic Fibrosis Treatment Arcturus Therapeutics announced encouraging interim results from its Phase 2 trial of ARCT-032, an inhaled mRNA therapy for cystic fibrosis. Early data shows safety, tolerance, and signs of therapeutic efficacy, particularly in mucus reduction. The company plans further studies to validate these findings.
August 11, 2025 Arcturus Therapeutics Holdings Inc.: Q2 2025 Financial Report Arcturus Therapeutics Holdings Inc. released its Q2 2025 financial report, highlighting the commercialization of its mRNA vaccine KOSTAIVE and ongoing clinical advancements. Despite a revenue decline, the company shows improved operational efficiency and a strong cash position, positioning itself for future growth in the biotech sector.
May 12, 2025 Arcturus Therapeutics Holdings Inc. Reports Q1 2025: A Transition to Commercial Success Amidst Financial Challenges Arcturus Therapeutics reported its Q1 2025 results, marking significant progress with the launch of KOSTAIVE® but facing financial hurdles. Revenue declined amid operational losses, emphasizing the need for strategic funding to support future developments.
May 12, 2025 Arcturus Therapeutics Reports First Quarter 2025 Financial Results and Pipeline Developments Arcturus Therapeutics reported its Q1 2025 financial results, showing a reduced net loss and progress in its cystic fibrosis and OTC deficiency programs. The company received FDA Fast Track Designation for its mRNA vaccine candidate and is positioned for future growth in therapeutic innovations.
April 22, 2025 Arcturus Therapeutics to Announce First Quarter Financial Results and Corporate Update Arcturus Therapeutics will announce its Q1 2025 financial results on May 12, 2025, followed by a conference call for stakeholders. The company continues to lead in mRNA innovations with a diverse pipeline and strong intellectual property.
April 10, 2025 Arcturus Therapeutics Secures FDA Fast Track Designation for ARCT-2304 Vaccine Arcturus Therapeutics has received FDA Fast Track Designation for its ARCT-2304 vaccine, aimed at combatting the H5N1 virus. This designation accelerates the vaccine's development and review process, highlighting its significance in pandemic preparedness with federal support and innovative delivery technology.
March 06, 2025 Arcturus Therapeutics Holdings Inc. Reports 2024 Annual Financial Results Arcturus Therapeutics reports a revenue decline in 2024 despite the successful launch of its mRNA COVID-19 vaccine, KOSTAIVE. The company faces challenges but maintains strong alliances for future growth in biotechnology.
March 06, 2025 Arcturus Therapeutics Reports Q4 and FY 2024 Financial Results and Pipeline Developments Arcturus Therapeutics announced its Q4 and FY 2024 financial results, showing a decline in revenue and increased net losses. The company remains optimistic about its pipeline advancements, including key mRNA therapies and vaccine developments, projecting growth through strategic partnerships and upcoming data releases.
March 05, 2025 Arcturus Therapeutics to Showcase Innovations at Leerink’s Global Healthcare Conference 2025 Arcturus Therapeutics will present at the Leerink Global Healthcare Conference 2025, highlighting its advancements in mRNA vaccines and therapies for various diseases. The company is recognized for its innovative technologies and strong global collaborations, which position it for significant growth in the biotech sector.
February 24, 2025 Arcturus Therapeutics Set to Announce Fourth Quarter and Full Year 2024 Financial Results Arcturus Therapeutics is set to release its fourth quarter and full year financial results on March 6, 2025. The event will include a conference call for investors to discuss the company's advancements in mRNA therapeutics, including its COVID-19 vaccine and strategic partnerships.
February 14, 2025 European Commission Approves KOSTAIVE®: A Milestone in COVID-19 Vaccination The European Commission has approved KOSTAIVE®, the first self-amplifying mRNA COVID-19 vaccine, developed by CSL and Arcturus. This approval facilitates access to the innovative vaccine across Europe, showcasing its superior efficacy and safety over traditional options.
January 29, 2025 SWOT Analysis of Arcturus Therapeutics Holdings Inc. in 2025 This article presents a SWOT analysis of Arcturus Therapeutics Holdings Inc. in 2025, focusing on its proprietary mRNA technologies and product pipeline. While the company shows promise in the biotech landscape, it faces financial challenges and intense competition that must be navigated for future success.
November 07, 2024 Arcturus Therapeutics Holdings Inc.: Q3 2024 Financial Report Unveils Key Developments and Challenges Arcturus Therapeutics' Q3 2024 report highlights strategic collaborations, significant clinical advancements, and financial challenges, including a revenue drop. The company aims for innovative growth despite exploring funding options to address future losses.
August 05, 2024 Arcturus Therapeutics Holdings Inc. Q2 2024 Financial Report: A Promising Turnaround Arcturus Therapeutics Holdings Inc. announced a major revenue increase in Q2 2024, driven by strategic collaborations and product advancements. Despite operational losses, the company shows promise in the biotechnology sector, particularly with successful vaccine developments.
May 08, 2024 Arcturus Therapeutics Holdings Inc. Reports Q1 2024 Results: Challenges and Progress Arcturus Therapeutics has made notable advancements in mRNA technology while facing financial challenges in Q1 2024. Despite a revenue decline, the company achieved key milestones, including successful vaccine trials and strategic collaborations.